BACKGROUND: Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis. A pivotal event in the development of atherosclerosis is macrophage foam cell formation. The ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 regulate macrophage cholesterol efflux and hence play a vital role in macrophage foam cell formation. We have previously found that chronic elevated glucose reduces ABCG1 expression. In the present study, we examined whether patients with type 2 diabetes mellitus had decreased ABCG1 and/or ABCA1, impaired cholesterol efflux, and increased macrophage foam cell formation. METHODS AND RESULTS: Blood was collected from patients with and without type 2 diabetes mellitus. Peripheral blood monocytes were differentiated into macrophages, and cholesterol efflux assays, immunoblots, histological analysis, and intracellular cholesteryl ester measurements were performed. Macrophages from patients with type 2 diabetes mellitus had a 30% reduction in cholesterol efflux with a corresponding 60% increase in cholesterol accumulation relative to control subjects. ABCG1 was present in macrophages from control subjects but was undetectable in macrophages from patients with type 2 diabetes mellitus. In contrast, ABCA1 expression in macrophages was similar in both control subjects and patients with type 2 diabetes mellitus. Macrophage expression of ABCG1 in both patients and control subjects was induced by treatment with the liver X receptor agonist TO-901317. Upregulation of liver X receptor dramatically reduced foam cell formation in macrophages from patients with type 2 diabetes mellitus. CONCLUSIONS: ABCG1 expression and cholesterol efflux are reduced in patients with type 2 diabetes mellitus. This impaired ABCG1-mediated cholesterol efflux significantly correlates with increased intracellular cholesterol accumulation. Strategies to upregulate ABCG1 expression and function in type 2 diabetes mellitus could have therapeutic potential for limiting the accelerated vascular disease observed in patients with type 2 diabetes mellitus.
BACKGROUND: Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis. A pivotal event in the development of atherosclerosis is macrophage foam cell formation. The ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 regulate macrophage cholesterol efflux and hence play a vital role in macrophage foam cell formation. We have previously found that chronic elevated glucose reduces ABCG1 expression. In the present study, we examined whether patients with type 2 diabetes mellitus had decreased ABCG1 and/or ABCA1, impaired cholesterol efflux, and increased macrophage foam cell formation. METHODS AND RESULTS: Blood was collected from patients with and without type 2 diabetes mellitus. Peripheral blood monocytes were differentiated into macrophages, and cholesterol efflux assays, immunoblots, histological analysis, and intracellular cholesteryl ester measurements were performed. Macrophages from patients with type 2 diabetes mellitus had a 30% reduction in cholesterol efflux with a corresponding 60% increase in cholesterol accumulation relative to control subjects. ABCG1 was present in macrophages from control subjects but was undetectable in macrophages from patients with type 2 diabetes mellitus. In contrast, ABCA1 expression in macrophages was similar in both control subjects and patients with type 2 diabetes mellitus. Macrophage expression of ABCG1 in both patients and control subjects was induced by treatment with the liver X receptor agonist TO-901317. Upregulation of liver X receptor dramatically reduced foam cell formation in macrophages from patients with type 2 diabetes mellitus. CONCLUSIONS: ABCG1 expression and cholesterol efflux are reduced in patients with type 2 diabetes mellitus. This impaired ABCG1-mediated cholesterol efflux significantly correlates with increased intracellular cholesterol accumulation. Strategies to upregulate ABCG1 expression and function in type 2 diabetes mellitus could have therapeutic potential for limiting the accelerated vascular disease observed in patients with type 2 diabetes mellitus.
Authors: Vidya V Kunjathoor; Maria Febbraio; Eugene A Podrez; Kathryn J Moore; Lorna Andersson; Stephanie Koehn; Jeongmi S Rhee; Roy Silverstein; Henry F Hoff; Mason W Freeman Journal: J Biol Chem Date: 2002-10-09 Impact factor: 5.157
Authors: Angel Baldán; Liming Pei; Richard Lee; Paul Tarr; Rajendra K Tangirala; Michael M Weinstein; Joy Frank; Andrew C Li; Peter Tontonoz; Peter A Edwards Journal: Arterioscler Thromb Vasc Biol Date: 2006-08-03 Impact factor: 8.311
Authors: Ruud Out; Menno Hoekstra; Reeni B Hildebrand; Janine K Kruit; Illiana Meurs; Zhaosha Li; Folkert Kuipers; Theo J C Van Berkel; Miranda Van Eck Journal: Arterioscler Thromb Vasc Biol Date: 2006-07-20 Impact factor: 8.311
Authors: Matthew A Kennedy; Gabriel C Barrera; Kotoka Nakamura; Angel Baldán; Paul Tarr; Michael C Fishbein; Joy Frank; Omar L Francone; Peter A Edwards Journal: Cell Metab Date: 2005-02 Impact factor: 27.287
Authors: A Venkateswaran; B A Laffitte; S B Joseph; P A Mak; D C Wilpitz; P A Edwards; P Tontonoz Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: Melissa E Hatley; Suseela Srinivasan; Kelly B Reilly; David T Bolick; Catherine C Hedrick Journal: J Biol Chem Date: 2003-05-06 Impact factor: 5.157
Authors: Jeffrey M Sturek; J David Castle; Anthony P Trace; Laura C Page; Anna M Castle; Carmella Evans-Molina; John S Parks; Raghavendra G Mirmira; Catherine C Hedrick Journal: J Clin Invest Date: 2010-06-07 Impact factor: 14.808
Authors: David W Draper; Kymberly M Gowdy; Jennifer H Madenspacher; Rhonda H Wilson; Gregory S Whitehead; Hideki Nakano; Arun R Pandiri; Julie F Foley; Alan T Remaley; Donald N Cook; Michael B Fessler Journal: J Immunol Date: 2012-04-25 Impact factor: 5.422
Authors: Hemant Kulkarni; Mark Z Kos; Jennifer Neary; Thomas D Dyer; Jack W Kent; Harald H H Göring; Shelley A Cole; Anthony G Comuzzie; Laura Almasy; Michael C Mahaney; Joanne E Curran; John Blangero; Melanie A Carless Journal: Hum Mol Genet Date: 2015-06-22 Impact factor: 6.150